Here are the Form 4 insider transactions from Liminatus Pharma, Inc. Warrants (LIMNW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LIMNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIMNW filings page.
Liminatus Pharma, Inc. reported that Valetudo Therapeutics LLC, a greater-than-10% holder controlled by CEO Chris Kim, received 3,448,926 shares of common stock and 48,975.10742 shares of Series A Non-Voting Convertible Preferred Stock as consideration in the acquisition of InnocsAI LLC. Following the transaction, Valetudo holds 5,244,351 common shares and a preferred position convertible into 489,751,074 common shares, with each preferred share convertible into 10,000 common shares at an issue price of $0.20 per share. Conversion of the preferred stock is contingent on prior stockholder approval under applicable Nasdaq Stock Market LLC listing rules. Kim may be deemed the beneficial owner of Valetudo’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Liminatus Pharma insider filing reports an internal share transfer by a major holder. Valetudo Therapeutics LLC, a ten percent owner associated with CEO and director Chris Kim, transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd. for no payment of consideration.
Valetudo retains voting power over the transferred shares under a voting agreement and continues to hold 1,795,803 shares of Liminatus Pharma common stock of record. Kim may be deemed the beneficial owner through his control of Valetudo but disclaims beneficial ownership beyond his ultimate pecuniary interest.